CYDY Insider Trading Activity and SEC Form 4 Filings
CYDY insider trading summary
No open-market insider purchases or sales of CytoDyn Inc. (CYDY) have been reported on SEC Form 4 in the past 12 months.
Latest CYDY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 22, 2020 | Michael D. Mulholland | Chief Financial Officer | Sell | $85K (12,100 @ $7.00) |
| Dec 22, 2020 | Michael D. Mulholland | Chief Financial Officer | Sell | $3.0M (453,997 @ $6.61) |
| Dec 22, 2020 | Michael D. Mulholland | Chief Financial Officer | Sell | $1.3M (245,704 @ $5.49) |
| Nov 2, 2020 | Jordan G Naydenov | Director | Buy | $497K (193,500 @ $2.57) |
| Oct 23, 2020 | Arian Colachis | GC and Corporate Secretary | Buy | $25K (10,000 @ $2.50) |
| Oct 23, 2020 | Jordan G Naydenov | Director | Buy | $298K (120,000 @ $2.49) |
| May 4, 2020 | Nader Pourhassan | President & CEO | Sell | $3.4M (1,201,652 @ $2.79) |
| May 1, 2020 | Scott A. Kelly | Chief Medical Officer | Buy | $141K (250,000 @ $0.56) |
| May 1, 2020 | Nader Pourhassan | President & CEO | Sell | $4.6M (1,399,685 @ $3.26) |
| May 1, 2020 | Scott A. Kelly | Chief Medical Officer | Sell | $3.9M (1,200,000 @ $3.26) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.